This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
29 Apr 2020

Catalent to manufacture J&J's lead COVID-19 vaccine candidate

Collaboration includes joint investment and tech transfer to prepare for rapid scale-up and segregated cGMP commercial manufacturing capacity.

Catalent is to collaborate with the Janssen Pharmaceutical Companies of Johnson & Johnson (J&J), whereby Catalent’s Biologics business unit will accelerate the availability of manufacturing capacity and prepare for large-scale commercial manufacturing of J&J's lead vaccine candidate for COVID-19 at its facility in Bloomington, Indiana.

The collaboration commits joint investment to accelerate the rapid scale-up of segregated manufacturing capacity over the coming months to support dedicated production of J&J’s investigational vaccine candidate.

Catalent plans to hire approximately 300 additional employees at the site for this program starting in July 2020 to meet operational readiness and 24x7 manufacturing schedules by January 2021.

“Catalent is proud to collaborate with J&J in its efforts to combat the coronavirus pandemic and save lives,” said John Chiminski, Chair and Chief Executive Officer of Catalent. “Both organizations have committed to ambitious goals and are executing innovative strategies to meet the forecasted demand on an unprecedented timeline. We value the trust that J&J has placed in us regarding this important, time-sensitive program and will apply our extensive experience in quickly scaling up manufacturing operations for late-stage and commercial products.”

Mentioned Companies
Catalent Pharma Solutions
View company profile

Related News